GSK (NYSE:GSK) Updates FY 2025 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.090-2.130 for the period, compared to the consensus EPS estimate of 4.520. The company issued revenue guidance of $40.1 billion-$40.9 billion, compared to the consensus revenue estimate of $34.3 billion.

Analysts Set New Price Targets

Several research firms recently weighed in on GSK. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Down 3.5 %

NYSE:GSK traded down $1.33 during midday trading on Thursday, reaching $36.38. The company had a trading volume of 7,166,655 shares, compared to its average volume of 4,648,455. GSK has a 12-month low of $31.72 and a 12-month high of $45.92. The firm has a market capitalization of $75.39 billion, a price-to-earnings ratio of 23.62, a PEG ratio of 1.38 and a beta of 0.64. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock’s fifty day simple moving average is $34.17 and its 200-day simple moving average is $37.60.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. On average, sell-side analysts anticipate that GSK will post 3.92 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a yield of 4.32%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.